Snowball logo
logo
3880

Medtide Inc

3880 • HK
HK$19.55-HK$0.08  (0.41%)
Estimate
Beta
-0.04
Forecast
P/E (FWD)
10
EPS (FWD)
1.96
About the company
Ticker
3880
ISIN
Country
China
Sector (GICS)
Other
Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, pre-clinical research, clinical development, and commercial-stage production services. It offers peptide new chemical entity discovery synthesis, manufacturing, and control development and commercial manufacturing services. The company focuses on developing oral and/or injectable glucagon, such as peptide-1 (GLP-1) molecule products. Its research and development technology platforms include OmniPeptSynth, PeptiConjuX, PeptiNuclide LinkTech, GreenSynth Innovations, and Impurity Screening. It serves customers in China, the United States, Japan, Europe, South Korea, and Australia. The company was formerly known as Taide Pharmaceutical (Zhejiang) Co., Ltd and changed its name to Medtide Inc. in February 2023. Medtide Inc. was incorporated in 2020 and is headquartered in Hangzhou, China.

Frequently asked questions

What sector does Medtide Inc (3880) operate in?

Medtide Inc belongs to the Other sector and operates in the Biotechnology industry.

What is Medtide Inc (3880) current stock price?

As of the latest data, Medtide Inc stock price is HK$19.55, with a previous close of HK$19.63. Medtide Inc lost -HK$0.08 in the last trading session, representing a -0.41% loss.

What is Medtide Inc (3880) current market capitalization?

Medtide Inc market cap is approximately 2.77 billion.

Does Medtide Inc (3880) pay dividends?

No. Medtide Inc does not pay a dividend.

What is Medtide Inc (3880) beta (volatility) score?

Medtide Inc has a beta of -0.040, indicating lower volatility than the overall market.